Biotech RadarJobs updated

COMPANY

PrimeVax Immuno-Oncology

primevax.com ↗

Clinical Phase 1

Keywords: oncology cancer Advanced Melanoma Metastatic Melanoma Dengue Virus-1 #45AZ5 (PV-001-DV) PV-001-DC

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma source ↗
  2. Trial start Phase 1: Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma source ↗
  3. Trial start Phase 1: Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma source ↗

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT03803397Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With MelanomaPhase 1Unknown status (ClinicalTrials.gov)Apr 1, 2024Aug 30, 2024 (estimated)
NCT03990493Intratumoral Injection of PV-001-DV Plus DC in Patients With MelanomaPhase 1Unknown status (ClinicalTrials.gov)Apr 1, 2024Sep 30, 2024 (estimated)
NCT03989895Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With MelanomaPhase 1Unknown status (ClinicalTrials.gov)Apr 1, 2024Sep 30, 2024 (estimated)
Feedback